Equities

Kancera AB

Kancera AB

Actions
  • Price (SEK)1.94
  • Today's Change0.002 / 0.10%
  • Shares traded123.27k
  • 1 Year change-60.68%
  • Beta1.3455
Data delayed at least 15 minutes, as of Sep 18 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-53.07m
  • Incorporated2010
  • Employees5.00
  • Location
    Kancera ABKarolinska Institutet Science ParkNanna Svartz Vag 4SOLNA 171 65SwedenSWE
  • Phone+46 850126080
  • Websitehttps://kancera.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Exact Therapeutics AS0.00-46.59m160.81m8.00--3.70-----1.51-1.510.001.410.00-------67.21-40.21-86.14-45.67-----------16,578.570.0258-------20.52------
AlzeCure Pharma AB0.00-35.87m180.12m11.00--4.41-----0.5371-0.53710.000.46250.00----0.00-75.21-52.78-89.05-57.01------------0.00------33.91------
Biosergen AB0.00-26.60m187.62m2.00--12.13-----0.286-0.2860.000.05570.00----0.00-145.58---216.30--------------0.00------32.25------
Lumito AB (publ)17.00k-26.38m193.73m14.00--1.80--11,395.89-0.1268-0.12680.000080.45980.0001--0.00961,133.33-20.54-20.77-23.68-22.3844,594.29---155,169.10--1.32-24.400.1569------4.56------
Acousort AB3.44m-19.30m207.58m----13.57--60.36-1.33-1.330.23791.020.14614.081.96---81.99-48.62-137.70-69.77-159.41-68.05-561.21-299.581.91--0.00--11.5138.81-24.01------
Thor Medical ASA0.00-17.89m221.87m1.00--0.8852-----0.08730.0210.001.110.00----0.00-9.82-79.17-10.54-113.94------------0.0035--------------
SenzaGen AB55.29m-20.60m222.76m32.00--2.43--4.03-0.8299-0.82992.233.110.50193.325.801,626,029.00-18.70-25.84-23.34-29.8571.6368.62-37.27-132.292.76-51.340.0443--19.3990.3211.30---21.10--
Ascelia Pharma AB0.00-61.78m224.83m13.00--2.45-----1.26-1.260.000.95540.00----0.00-52.75---65.92-------------40.420.4167------16.72------
Biovica International AB7.25m-115.45m228.68m27.00--2.56--31.54-1.73-1.730.10551.060.058417.304.76226,593.80-92.98-51.94-110.37-58.18-394.72-576.01-1,592.15-2,217.413.47--0.0721--115.4919.39-12.97---54.31--
Kancera AB0.00-53.07m234.86m5.00--2.83-----0.5955-0.59550.000.68490.00----0.00-56.73-54.82-66.40-66.21--96.28---7,249.06----0.00-------23.64------
Xbrane Biopharma AB191.89m-340.89m276.84m71.00--0.909--1.44-1.01-1.260.34030.19910.2090.702824.132,063,301.00-37.14-40.98-66.96-67.2443.32---177.65-364.401.07-20.510.357--314.3363.42-91.10--60.02--
Intervacc AB9.78m-102.66m287.80m15.00--1.42--29.43-1.36-1.360.12912.680.03553.191.62651,933.30-37.23-17.62-40.38-18.77-551.10-243.59-1,049.76-626.902.90--0.0006---17.23-25.79-60.31---38.72--
Xintela AB381.00k-40.83m290.07m--------761.33-0.0817-0.08170.0008-0.03190.0306--0.0493---327.65-181.06---391.61100.00---10,717.06-235,894.00---203.91-------45.5418.32---61.47--
Abliva AB137.00k-102.13m296.26m6.00--2.88--2,162.51-0.0928-0.09280.00010.06380.0013--0.0062---93.81-74.59-103.87-86.98-35,826.28---74,542.34-65,958.89----0.00--341.9493.89-12.02---19.74--
Annexin Pharmaceuticals AB (publ)0.00-52.36m298.47m4.00--8.28-----0.1873-0.18730.000.06760.00----0.00-162.59-125.42-220.41-151.33------------0.00-------8.17------
Data as of Sep 18 2024. Currency figures normalised to Kancera AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 30 Aug 202422.15k0.02%
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.